How to widen the hunt for targeted cancer therapy

Neergaard, Lauran
October 2010
Adirondack Daily Enterprise;10/2/2010, Vol. 117 Issue 233, pB6
The article provides information concerning the application of targeted cancer therapy in the U.S.


Related Articles

  • Therapeutics: A glimpse of the future. Goldring, Owen // Nature;3/26/1998, Vol. 392 Issue 6674, p420 

    Discusses the future of cancer therapeutics. Expectation of a new generation of anti-cancer drugs; Focus on finding inhibitors that target or starve cancers; Possibility that cancers may develop resistance to drugs; Techniques used at drug-discovery programs; Skills needed in cancer...

  • Identification of novel inhibitors of mitogen-activated protein kinase phosphatase-1 with structure-based virtual screening. Park, Hwangseo; Jeon, Jeong-Yi; Kim, Song; Jeong, Dae; Ryu, Seong // Journal of Computer-Aided Molecular Design;May2011, Vol. 25 Issue 5, p469 

    Mitogen-activated protein kinase phosphatase-1 (MKP-1) has proved to be an attractive target for the development of therapeutics for the treatment of cancer. We report the first example for a successful application of the structure-based virtual screening to identify the novel inhibitors of...

  • Chasing Mutations in the Epidermal Growth Factor in Lung Cancer. Dowell, Jonathan E.; Minna, John D. // New England Journal of Medicine;2/24/2005, Vol. 352 Issue 8, p830 

    Discusses the treatment of non-small-cell lung cancer. Incidence of non-small-cell lung cancer in the U.S.; Details of research on several treatments for non-small-cell lung cancer; Research into the development of mutations in the pathogenesis of lung cancer.

  • The Impact of BRCA Mutation on Ovarian Cancer Treatment Outcomes. Coleman, Robert L. // OB/GYN Clinical Alert;Jan2009, Vol. 25 Issue 9, p65 

    BRCA mutation carriers demonstrate improved survival characteristics relative to age- and stage-matched population controls. The performance gains are likely due to higher than expected platinum-based cytotoxicity and have implications for future therapeutic investigation.

  • Editorial [Hot Topic:Metalloproteinases Revisited (Guest Editor: Marcia L. Moss)]. Moss, Marcia L. // Current Pharmaceutical Biotechnology;Feb2008, Vol. 9 Issue 1, p1 

    Extensive research has gone into the area of metalloproteinases since the introduction of captopril as an inhibitor of angiotensin converting enzyme for the treatment of hypertension. Matrix metalloproteinases were favorite targets of pharmaceutical companies, with over 2,000 patents issued....

  • Molecular Pathways Underlying IBD-Associated Colorectal Neoplasia: Therapeutic Implications. Goel, Gati A.; Kandiel, Ahmed; Achkar, Jean Paul; Lashner, Bret // American Journal of Gastroenterology;Apr2011, Vol. 106 Issue 4, p719 

    Chronic inflammatory diseases, depending upon the duration and severity, are frequently associated with an increased risk of developing cancer. A classic paradigm is the enhanced risk of colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD). Carcinogenesis is a multifactorial...

  • Research and Markets: Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development.  // Biomedical Market Newsletter;5/5/2011, p118 

    The article presents a case study of personalized cancer therapy. It notes that cancer treatment has seen a dramatic shift with the addition of molecular targeted therapies, driving the pharmaceutical industry to search for disease and patient characteristics which confer the best response...

  • Chronic Pancreatitis and Systemic Inflammatory Response Syndrome Prevent Impact of Chemotherapy with Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer. Knoop, Richard F.; Sparn, Moritz; Waldmann, Jens; Plassmeier, Lars; Bartsch, Detlef K.; Lauth, Matthias; Hudemann, Christoph; Fendrich, Volker // Neoplasia;Jun2014, Vol. 16 Issue 6, p463 

    BACKGROUND AND AIMS: Gemcitabine is the standard therapy for patients with pancreatic cancer with metastatic disease. Patients with metastatic pancreatic cancer presenting with increased values of C-reactive protein do not respond to gemcitabine. So far, no studies have evaluated the correlation...

  • Management of breast cancer--Part II. Turner, Nicholas C.; Jones, Alison L. // BMJ: British Medical Journal (International Edition);7/19/2008, Vol. 337 Issue 7662, p164 

    Breast cancer comprises a spectrum of related but different cancer subtypes, which have different causal genetic changes, may follow different clinical courses, and require different treatments tailored to the phenotype (fig 1). Here, in this second part of our review on breast cancer, we...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics